Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus - Top-Institutions - MDSpire

Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus

  • By

  • Alice Giontella

  • Mikael Åkerlund

  • Kevin Bronton

  • Cristiano Fava

  • Luca A Lotta

  • Aris Baras

  • John D Overton

  • Marcus Jones

  • Andreas Bergmann

  • Paul Kaufmann

  • Yulia Ilina

  • Olle Melander

  • August 13, 2024

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Genetics
    • Metabolic Disease Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Genomic Medicine
    • Muscle Biology

  • #3

    University of Oxford
    University of Oxford

    Oxford, UK

    Key Differentiators

    • Genetics
    • Endocrinology
    • Population Health

  • #4

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, Sweden

    Key Differentiators

    • Endocrinology
    • Genetic Epidemiology
    • Muscle Physiology

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Molecular Genetics
    • Metabolic Disorders

Original Source(s)

Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus

  • by Alice Giontella, Mikael Åkerlund, Kevin Bronton, Cristiano Fava, Luca A Lotta, Aris Baras, John D Overton, Marcus Jones, Andreas Bergmann, Paul Kaufmann, Yulia Ilina, Olle Melander

  • August 13, 2024

Related Content

Suprachoroidal Injection in the Treatment of Diabetic Macular Edema: Mechanisms, Clinical Advances, and Future Perspectives

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

AACE 2026: AI moves from hype to reality in diabetes care

"Right now, AI is more of a copilot, but the long-term vision is something much closer to autopilot."